Showing 301 - 320 results of 1,447 for search '"liver disease"', query time: 0.07s Refine Results
  1. 301

    Western diet promotes the progression of metabolic dysfunction‐associated steatotic liver disease in association with ferroptosis in male mice by Nicole Maddie, Nefia Chacko, David Matatov, Maria Alicia Carrillo‐Sepulveda

    Published 2024-11-01
    “…Abstract Non‐alcoholic fatty liver disease (NAFLD), now referred to as metabolic dysfunction‐associated steatotic liver disease (MASLD), is a silent killer that often progresses to metabolic dysfunction‐associated steatohepatitis (MASH). …”
    Get full text
    Article
  2. 302
  3. 303
  4. 304
  5. 305

    The Effectiveness of Liraglutide in Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus Compared to Sitagliptin and Pioglitazone by Takamasa Ohki, Akihiro Isogawa, Masahiko Iwamoto, Mitsuru Ohsugi, Haruhiko Yoshida, Nobuo Toda, Kazumi Tagawa, Masao Omata, Kazuhiko Koike

    Published 2012-01-01
    “…Liraglutide leading to improve not only glycaemic control but also liver inflammation in non-alcoholic fatty liver disease (NAFLD) patients. Aims. The aim of this study is to elucidate the effectiveness of liraglutide in NAFLD patients with type 2 diabetes mellitus (T2DM) compared to sitagliptin and pioglitazone. …”
    Get full text
    Article
  6. 306

    Insulin resistance as a mediator in the association between nickel exposure and metabolic dysfunction-associated steatotic liver disease by Zhou Liu, Liang Zhang, Yanrui Wu, Zongbiao Tan, Guang Li, Zhenwen Li, Liying Zhan, Weiguo Dong

    Published 2025-01-01
    “…Nevertheless, a notable research gap persists, as there is currently insufficient direct investigation elucidating the intricate interplay between nickel exposure and the risk of metabolic dysfunction-associated steatotic liver disease (MASLD). Methods The data utilized in this study was sourced from the National Health and Nutrition Examination Survey 2017–2020. …”
    Get full text
    Article
  7. 307

    Association of Serum Adiponectin, Leptin, and Resistin Concentrations with the Severity of Liver Dysfunction and the Disease Complications in Alcoholic Liver Disease by Beata Kasztelan-Szczerbinska, Agata Surdacka, Maria Slomka, Jacek Rolinski, Krzysztof Celinski, Agata Smolen, Mariusz Szczerbinski

    Published 2013-01-01
    “…There is growing evidence that white adipose tissue is an important contributor in the pathogenesis of alcoholic liver disease (ALD). We investigated serum concentrations of total adiponectin (Acrp30), leptin, and resistin in patients with chronic alcohol abuse and different grades of liver dysfunction, as well as ALD complications. …”
    Get full text
    Article
  8. 308
  9. 309

    Association between sleep duration and risk of nonalcoholic fatty liver disease: A systematic review and meta-analysis by Kasra Pirahesh, Ali Zarrinnia, Leila Nikniaz, Zeinab Nikniaz

    Published 2025-02-01
    “…Introduction: Considering that both long and short sleep duration may have an association with nonalcoholic fatty liver disease (NAFLD), in this meta-analysis, we analyzed the dose-response association between sleep duration and NAFLD along with meta-analyses of the differences in mean sleep duration between NAFLD patients and healthy controls, and linear meta-analysis of the association between sleep duration and NAFLD. …”
    Get full text
    Article
  10. 310
  11. 311

    Treatment of end-stages of liver disease in outcome of persistent hepatitis C virus infection at deficiency of donor organs by Ye. N. German, M. V. Mayevskaya, O. I. Andreytseva, V. T. Ivashkin, A. V. Chzhao, A. G. Serova, G. V. Mikhaylovskaya, I. Yu. Pirogova

    Published 2011-03-01
    “…According to actual data it was proved, that antibodies to cor-antigen of hepatitis B virus at patients with persistent hepatitis С virus infection do not alter biochemical activity and severity of liver disease. With application of prognostic models tendency to higher risk of end-stages of liver disease development at patients with persistent hepatitis B virus infection and anti-HBcor IgG in blood serum was revealed. …”
    Get full text
    Article
  12. 312

    Model for End-Stage Liver Disease and Sodium Velocity Predicts Overall Survival in Nonmetastatic Hepatocellular Carcinoma Patients by Justin Y. Tang, Nitin Ohri, Rafi Kabarriti, Santiago Aparo, Jennifer Chuy, Sanjay Goel, Jonathan M. Schwartz, Milan Kinkhabwala, Andreas Kaubisch, Chandan Guha

    Published 2018-01-01
    “…The significance of short-term changes in model for end-stage liver disease and Sodium (MELD-Na) following hepatocellular carcinoma (HCC) diagnosis is unknown. …”
    Get full text
    Article
  13. 313
  14. 314
  15. 315

    Dietary Interventions and Physical Activity as Crucial Factors in the Prevention and Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease by Paweł Rajewski, Jakub Cieściński, Piotr Rajewski, Szymon Suwała, Alicja Rajewska, Maciej Potasz

    Published 2025-01-01
    “…Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide and affects nearly 30% of the adult population and 10% of the pediatric population. …”
    Get full text
    Article
  16. 316

    Prevalence of non-alcoholic fatty liver disease in out-patients of the Russian Federation: DIREG 2 study results by V. T. Ivashkin, O. M. Drapkina, I. V. Mayev, A. S. Trukhmanov, D. V. Blinov, L. K. Palgova, V. V. Tsukanov, T. I. Ushakova

    Published 2015-12-01
    Subjects: “…direg 2, epidemiology, nafld, nonalcoholic fatty liver disease, nash, non-alcoholic steatohepatitis, prevalence…”
    Get full text
    Article
  17. 317
  18. 318
  19. 319
  20. 320